Mammograms haven’t cut rate of advanced breast cancer

BOSTON (AP) – A new report raises fresh questions about the value of mammograms. The rate of cancers in the United States that have already spread far beyond the breast when they are discovered has stayed stable for decades, suggesting that screening and early detection are not preventing the most dangerous forms of the disease.

The report, in Thursday’s New England Journal of Medicine, is by three prominent cancer specialists and is based on federal statistics going back to the 1970s.

It comes a week after the American Cancer Society scaled back its mammography advice, saying most women should start annual screening at age 45, not 40, and switch to every other year at 55. A government task force recommends even less – every other year starting at 50.

“We’re undergoing what I think for the public is a very confusing debate’’ about screening, but it’s really “a course correction’’ prompted by more awareness of its risks and benefits to various groups of women, said Dr. H. Gilbert Welch, a health policy expert at Dartmouth Medical School. “All they heard for years was, ‘there are only benefits.’’’

“Screening offers hope that cancer can be detected in an early, localized phase when it’s more amenable to treatment,’’ they write, but that assumes that cancer starts in one place, grows and then spreads. If that was always true, screening would reduce the rate of advanced cancers.

And that has not happened. The rate of breast cancers detected at an advanced stage has been stable since 1975, despite wide use of mammography since the 1980s. The average age of women diagnosed with cancer also has remained around 63, another sign cancers are not being found sooner.

The trends suggest that some breast cancers are already “systemic’’ or widely spread from the start, and that finding them sooner has limited impact.

“Screening mammography has been unable to identify those bad cancers, destined to become metastatic, at an earlier stage. That doesn’t say mammography doesn’t help less aggressive cancers,’’ but those are less likely to prove deadly, Welch said.